Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

LCTX 11.07.2024

Full Press ReleaseSEC FilingsOur LCTX Tweets

About Gravity Analytica

Recent News

  • 01.06.2025 - Lineage Cell Therapeutics Issues Letter to Stockholders
  • 11.21.2024 - Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
  • 11.20.2024 - Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Recent Filings

  • 12.09.2024 - DEF 14A Other definitive proxy statements
  • 11.29.2024 - PRE 14A Other preliminary proxy statements
  • 11.26.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 7, 2024--Lineage Cell Therapeutics, Inc.(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results onThursday, November 14, 2024, following the close of theU.S.financial markets. Lineage management will also host a conference call and webcast onThursday, November 14, 2024, at4:30 p.m. Eastern Time/1:30 p.m. Pacific Timeto discuss its third quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call onNovember 14, 2024, by dialing (800) 715-9871 from theU.S.andCanadaand should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in theInvestorssection of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available throughNovember 21, 2024, by dialing (800) 770-2030 from theU.S.andCanadaand entering conference ID number 2238934.

AboutLineage Cell Therapeutics, Inc.

Lineage Cell Therapeuticsis a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche andGenentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonanceTM (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visitwww.lineagecell.comor follow the company on X/Twitter@LineageCell.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241107087038/en/

Lineage Cell Therapeutics, Inc.IRIoana C. Hone(ir@lineagecell.com)(442) 287-8963

Russo Partners– Media RelationsNic JohnsonorDavid Schull(Nic.johnson@russopartnersllc.com)(David.schull@russopartnersllc.com)(212) 845-4242

Source:Lineage Cell Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com